Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome

L. W. Cho, E. S. Kilpatrick, B. G. Keevil, A. M. Coady, Stephen Atkin

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Context: Mean insulin resistance (IR) is greater and it is also more variable in overweight women with polycystic ovarian syndrome (PCOS) compared to weight matched controls. Whilst treatment will reduce the mean IR, it is not known if the IR variability is also reduced. Objective: To compare the change in IR and its variability before and after treatment with insulin sensitization through metformin and pioglitazone, compared to that induced by weight loss with orlistat. Design: Randomized, open labelled parallel study. Setting: Endocrinology outpatient clinic at a referral centre. Patients: Thirty obese PCOS patients [BMI 36.0 ± 1.2 kg/m2 (mean ± SEM)] participated in the study. Intervention: The change in biological variability (BV) was assessed by measuring IR (homeostasis model assessment method) at 4-day intervals on 10 consecutive occasions before and 12 weeks after randomization to metformin, pioglitazone or orlistat. Outcome measured: The primary end point of the study was a change in BV of IR. Results: Treatment with pioglitazone, orlistat and metformin reduced the overall IR by 41.0 ± 4.1%, 19.7 ± 6.4% and 16.1 ± 6.8% (P = 0.005, P = 0.013, P = 0.17, respectively) and IR variability by 28.5 ± 18.0%, 41.8 ± 11.6% and 23.7 ± 17.0 (P = 0.20, P = 0.015 and P = 0.28, respectively). Free androgen index reduced significantly with all treatments. Conclusion: Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalClinical Endocrinology
Volume70
Issue number2
DOIs
Publication statusPublished - Feb 2009
Externally publishedYes

Fingerprint

pioglitazone
Polycystic Ovary Syndrome
Metformin
Insulin Resistance
Therapeutics
Hyperandrogenism
orlistat
Endocrinology
Random Allocation

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. / Cho, L. W.; Kilpatrick, E. S.; Keevil, B. G.; Coady, A. M.; Atkin, Stephen.

In: Clinical Endocrinology, Vol. 70, No. 2, 02.2009, p. 233-237.

Research output: Contribution to journalArticle

@article{a3008c9315ae42c095ff07d3f15437b3,
title = "Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome",
abstract = "Context: Mean insulin resistance (IR) is greater and it is also more variable in overweight women with polycystic ovarian syndrome (PCOS) compared to weight matched controls. Whilst treatment will reduce the mean IR, it is not known if the IR variability is also reduced. Objective: To compare the change in IR and its variability before and after treatment with insulin sensitization through metformin and pioglitazone, compared to that induced by weight loss with orlistat. Design: Randomized, open labelled parallel study. Setting: Endocrinology outpatient clinic at a referral centre. Patients: Thirty obese PCOS patients [BMI 36.0 ± 1.2 kg/m2 (mean ± SEM)] participated in the study. Intervention: The change in biological variability (BV) was assessed by measuring IR (homeostasis model assessment method) at 4-day intervals on 10 consecutive occasions before and 12 weeks after randomization to metformin, pioglitazone or orlistat. Outcome measured: The primary end point of the study was a change in BV of IR. Results: Treatment with pioglitazone, orlistat and metformin reduced the overall IR by 41.0 ± 4.1{\%}, 19.7 ± 6.4{\%} and 16.1 ± 6.8{\%} (P = 0.005, P = 0.013, P = 0.17, respectively) and IR variability by 28.5 ± 18.0{\%}, 41.8 ± 11.6{\%} and 23.7 ± 17.0 (P = 0.20, P = 0.015 and P = 0.28, respectively). Free androgen index reduced significantly with all treatments. Conclusion: Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study.",
author = "Cho, {L. W.} and Kilpatrick, {E. S.} and Keevil, {B. G.} and Coady, {A. M.} and Stephen Atkin",
year = "2009",
month = "2",
doi = "10.1111/j.1365-2265.2008.03309.x",
language = "English",
volume = "70",
pages = "233--237",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome

AU - Cho, L. W.

AU - Kilpatrick, E. S.

AU - Keevil, B. G.

AU - Coady, A. M.

AU - Atkin, Stephen

PY - 2009/2

Y1 - 2009/2

N2 - Context: Mean insulin resistance (IR) is greater and it is also more variable in overweight women with polycystic ovarian syndrome (PCOS) compared to weight matched controls. Whilst treatment will reduce the mean IR, it is not known if the IR variability is also reduced. Objective: To compare the change in IR and its variability before and after treatment with insulin sensitization through metformin and pioglitazone, compared to that induced by weight loss with orlistat. Design: Randomized, open labelled parallel study. Setting: Endocrinology outpatient clinic at a referral centre. Patients: Thirty obese PCOS patients [BMI 36.0 ± 1.2 kg/m2 (mean ± SEM)] participated in the study. Intervention: The change in biological variability (BV) was assessed by measuring IR (homeostasis model assessment method) at 4-day intervals on 10 consecutive occasions before and 12 weeks after randomization to metformin, pioglitazone or orlistat. Outcome measured: The primary end point of the study was a change in BV of IR. Results: Treatment with pioglitazone, orlistat and metformin reduced the overall IR by 41.0 ± 4.1%, 19.7 ± 6.4% and 16.1 ± 6.8% (P = 0.005, P = 0.013, P = 0.17, respectively) and IR variability by 28.5 ± 18.0%, 41.8 ± 11.6% and 23.7 ± 17.0 (P = 0.20, P = 0.015 and P = 0.28, respectively). Free androgen index reduced significantly with all treatments. Conclusion: Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study.

AB - Context: Mean insulin resistance (IR) is greater and it is also more variable in overweight women with polycystic ovarian syndrome (PCOS) compared to weight matched controls. Whilst treatment will reduce the mean IR, it is not known if the IR variability is also reduced. Objective: To compare the change in IR and its variability before and after treatment with insulin sensitization through metformin and pioglitazone, compared to that induced by weight loss with orlistat. Design: Randomized, open labelled parallel study. Setting: Endocrinology outpatient clinic at a referral centre. Patients: Thirty obese PCOS patients [BMI 36.0 ± 1.2 kg/m2 (mean ± SEM)] participated in the study. Intervention: The change in biological variability (BV) was assessed by measuring IR (homeostasis model assessment method) at 4-day intervals on 10 consecutive occasions before and 12 weeks after randomization to metformin, pioglitazone or orlistat. Outcome measured: The primary end point of the study was a change in BV of IR. Results: Treatment with pioglitazone, orlistat and metformin reduced the overall IR by 41.0 ± 4.1%, 19.7 ± 6.4% and 16.1 ± 6.8% (P = 0.005, P = 0.013, P = 0.17, respectively) and IR variability by 28.5 ± 18.0%, 41.8 ± 11.6% and 23.7 ± 17.0 (P = 0.20, P = 0.015 and P = 0.28, respectively). Free androgen index reduced significantly with all treatments. Conclusion: Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study.

UR - http://www.scopus.com/inward/record.url?scp=58549097078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58549097078&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2008.03309.x

DO - 10.1111/j.1365-2265.2008.03309.x

M3 - Article

VL - 70

SP - 233

EP - 237

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 2

ER -